{
    "clinical_study": {
        "@rank": "3438", 
        "brief_summary": {
            "textblock": "Gimatecan\u00ae is sigma-tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in\n      this class play a crucial role in destroying DNA replication in tumors. We are conducting\n      this study to determine the Maximum Tolerated Dose of our compound, when given as a capsule,\n      rather than by intravenous injection."
        }, 
        "brief_title": "This is an Early Study to Investigate the Effect of Gimatecan\u00ae in Adults With Solid Tumor", 
        "completion_date": {
            "#text": "February 2005", 
            "@type": "Actual"
        }, 
        "condition": "Solid Malignancies", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Histologically/cytologically proven advanced solid tumors\n\n          -  Life expectancy of at least 3 months with normal hematological, liver and renal\n             function\n\n        Exclusion criteria:\n\n          -  Pregnant and lactating patients\n\n          -  Participation in any investigating drug study within 4 weeks preceding treatment\n             start or concurrent treatment with any other anti-cancer therapy\n\n          -  Gastrointestinal dysfunction that could alter absorption or motility"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2002", 
        "id_info": {
            "nct_id": "NCT00033202", 
            "org_study_id": "ST 01-401"
        }, 
        "intervention": {
            "intervention_name": "Gimatecan\u00ae (ST-1481)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "keyword": [
            "Solid Tumor", 
            "Camptothecin", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "June 2, 2009", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02903"
                    }, 
                    "name": "Rhode Island Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase I Study of Oral ST1481 Administered Once Weekly Every 3 Out 4 Weeks in Patients With Advanced Solid Malignancies.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00033202"
        }, 
        "source": "Sigma-Tau Research, Inc.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Rhode Island Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Dana-Farber Cancer Institute", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Sigma-Tau Research, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2009"
    }, 
    "geocoordinates": {
        "Dana-Farber Cancer Institute": "42.358 -71.06", 
        "Massachusetts General Hospital": "42.358 -71.06", 
        "Rhode Island Hospital": "41.824 -71.413"
    }
}